## Current Evidence for the Treatment of NET and GIST:

## **Experts' Clinical Insights**

Friday, 26 September 2014

17.00 - 18.30

Pamplona Auditorium, IFEMA Convention and Congress Centre Madrid, Spain

17.00–17.05	Welcome and Introductions	Dermot O'Toole, MD, MRCPI – <i>Chair</i>
17.05–17.25	Advanced pNET: Optimal Treatment Sequence	Simron Singh, MD
17.25–17.35	Remaining Unmet Needs in NET	NET Panel and Chair
17.35–17.55	Challenges in the Diagnosis and Treatment of Lung NET	Rachel Riechelmann, MD, PhD
17.55–18.05	NET Q&A	NET Panel and Chair
18.05–18.20	Treatment in GIST: Clinical Challenges	Jean-Yves Blay, MD, PhD
18.20–18.25	GIST and Overall Q&A	Chair, Faculty Panel
18.25–18.30	Closing Remarks	Dermot O'Toole, MD, MRCPI – <i>Chair</i>

Novartis Pharma AG CH-4002 Basel Switzerland © Novartis 2014

July 2014 G-AFI-1095461

## Second-Line Treatment of mRCC:

## A "Virtual Tumor Board"

Friday, 26 September 2014

19.00 - 20.00

Pamplona Auditorium, IFEMA Convention and Congress Centre Madrid, Spain

19.00–19.10	Welcome and Introductions	Thomas Powles, MD, MRCP – Chair
19.10–19.15	Introduction to Community Oncologist Case background: presentation, diagnosis, first-line treatment, and progression: Virtual Teleconference	Thomas Powles, MD, MRCP – Moderator Emiliano Calvo, MD, PhD Christian Kollmannsberger, MD – Panel
19.15–19.55	Clinical Trial Data for Second-Line Therapy Real-World Evidence for Second- Line Therapy	Emiliano Calvo, MD, PhD  Christian Kollmannsberger, MD
19.55–20.00	Panel Discussion and Concluding Remarks	Thomas Powles, MD, MRCP – Chair

Novartis Pharma AG CH-4002 Basel Switzerland © Novartis 2014

July 2014

G-AFI-1095463

